2. Search Result
Search Result
Results for "

ATF2

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

6

Recombinant Proteins

1

Isotope-Labeled Compounds

6

Antibodies

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13241
    Ralimetinib dimesylate
    Maximum Cited Publications
    15 Publications Verification

    LY2228820 dimesylate

    		 p38 MAPK Autophagy Apoptosis Inflammation/Immunology Cancer
    Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.
    Ralimetinib dimesylate
  • HY-152860
    Darizmetinib

    HRX-0215

    		 p38 MAPK JNK NF-κB MDM-2/p53 Cancer
    Darizmetinib (HRX-0215) is an orally active, potent and selective inhibitor of mitogen-activated protein kinase kinase 4 (MKK4). Darizmetinib leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration. Darizmetinib is promising for research of preventing liver failure after extensive oncological liver resections or transplantation of small liver grafts [2] .
    Darizmetinib
  • HY-B1198
    Piperonyl butoxide
    1 Publications Verification

    ENT-14250

    		 Environmental Pollutants Parasite Infection Cancer
    Piperonyl butoxide (ENT-14250) is a pesticide synergist and food additive. Piperonyl butoxide has adverse effects on reproduction, development and behavior in mice. Piperonyl butoxide can activate c-Jun and ATF-2 in mouse hepatocytes. Piperonyl butoxide is a liver cancer carcinogen in rats and mice [2] .
    Piperonyl butoxide
  • HY-13241A
    Ralimetinib
    Maximum Cited Publications
    15 Publications Verification

    LY2228820

    		 p38 MAPK Autophagy Cancer
    Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC50 of 5.3 nmol/L against human p38α and an IC50 of 3.2 nmol/L against human p38β. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma [2].
    Ralimetinib
  • HY-134963
    SBI-0087702

    		PKC Cancer
    SBI-0087702 promots the cytoplasmic localization of ATF2 in melanoma cells. SBI-0087702-induced translocation of ATF2 to the mitochondria results in increased apoptosis due to loss of mitochondrial membrane integrity. SBI-0087702 also inhibits growth and motility of melanoma cells. SBI-0087702 was shown to inhibit ATF2 phosphorylation on Thr52 by PKCε .
    SBI-0087702
  • HY-RS17003
    Atf2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Atf2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Atf2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Atf2 Mouse Pre-designed siRNA Set A
    Atf2 Mouse Pre-designed siRNA Set A
  • HY-117987
    CPS-11

    N-(Hydroxymethyl)thalidomide

    		 Nuclear Factor of activated T Cells (NFAT) NF-κB Reactive Oxygen Species (ROS) Cancer
    CPS-11 (N-(Hydroxymethyl)thalidomide) a Thalidomide (HY-14658) analogue, is a potent anti-cancer agent. CPS-11 inhibits NF-κB, activates NFAT, and repress cytokine expression through elevated ROS. CPS-11 exhibits a wider activity spectrum and higher potency against MM (multiple myeloma) cell lines [2] .
    CPS-11
  • HY-RS01128
    ATF2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    ATF2 Human Pre-designed siRNA Set A contains three designed siRNAs for ATF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ATF2 Human Pre-designed siRNA Set A
    ATF2 Human Pre-designed siRNA Set A
  • HY-RS23446
    Atf2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Atf2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Atf2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Atf2 Rat Pre-designed siRNA Set A
    Atf2 Rat Pre-designed siRNA Set A
  • HY-B1198R
    Piperonyl butoxide (Standard)

    ENT-14250 (Standard)

    		 Parasite Reference Standards Infection Cancer
    Piperonyl butoxide (Standard) is the analytical standard of Piperonyl butoxide. This product is intended for research and analytical applications. Piperonyl butoxide (ENT-14250) is a pesticide synergist and food additive. Piperonyl butoxide has adverse effects on reproduction, development and behavior in mice. Piperonyl butoxide can activate c-Jun and ATF-2 in mouse hepatocytes. Piperonyl butoxide is a liver cancer carcinogen in rats and mice [2] .
    Piperonyl butoxide (Standard)
  • HY-B1198S
    Piperonyl butoxide-d9

    ENT-14250-d9

    		 Isotope-Labeled Compounds Parasite Infection Cancer
    Piperonyl butoxide-d9 is the deuterium labeled Piperonyl butoxide.Piperonyl butoxide (ENT-14250) is a pesticide synergist and food additive. Piperonyl butoxide has adverse effects on reproduction, development and behavior in mice. Piperonyl butoxide can activate c-Jun and ATF-2 in mouse hepatocytes. Piperonyl butoxide is a liver cancer carcinogen in rats and mice [2] .
    Piperonyl butoxide-d9
  • HY-W585976
    Benzo[a]pyrene diol epoxide

    		p38 MAPK Cancer
    Benzo[a]pyrene diol epoxide is a carcinogen present in tobacco smoke as well as in environmental pollution. Benzo[a]pyrene diol epoxide is a metabolite of benzo[a]pyrene (BaP) , which is polycyclic aromatic hydrocarbon (PAH) . Benzo[a]pyrene diol epoxide induces esophageal carcinogenesis. Benzo[a]pyrene diol epoxide may act to induce activation of ERKs and p38 MAPK marked by an increased level of phosphorylation of both the ERKs and p38 MAPK which corresponds with the increased activation of both kinases as evidenced by increased phsosphorylation of their substrates Elk-1 and ATF-2, respectively.
    Benzo[a]pyrene diol epoxide
  • HY-RS05361
    GDNF Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    GDNF Human Pre-designed siRNA Set A contains three designed siRNAs for GDNF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    GDNF Human Pre-designed siRNA Set A
    GDNF Human Pre-designed siRNA Set A
  • HY-180419
    SF-3-030

    		ERK Apoptosis c-Myc Inflammation/Immunology Cancer
    SF-3-030 is a potent, selective and non-ATP competitive ERK1/2 inhibitor. SF-3-030 selectively induces apoptosis in melanoma cells containing mutated BRaf and constitutively active ERK1/2 signalling. SF-3-030 mitigates multiple features of asthma in a murine model of asthma. SF-3-030 can be used for the research of asthma and melanomasup [2].
    SF-3-030

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: